FORT LAUDERDALE, Fla., June 27 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., announced today that Eric Milne, MD, FRCR, FRCP, Professor Emeritus of Radiology and Medicine, University of California, Irvine College of Medicine, IDSI Director of Clinical Research, presented a paper at the 2006 Fleischner Society meeting, June 18-24, in Vienna, Austria.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )
Professor Milne, a founding member of the 37-year old Society, presented his findings in a paper, "The Diagnosis of Diastolic Heart Failure," which discussed a previously unreported combination of plain chest X-ray findings and clinical presentation. The use of imaging findings in combination with clinical findings may permit an earlier and more frequent diagnosis of diastolic heart failure.
Tim Hansen, IDSI Chief Executive Officer, stated, "We are pleased to see Dr. Milne's continuing clinical and research activities. His history of clinical and academic leadership has contributed greatly to IDSI's efforts to bring the new CT laser breast imaging technology into the imaging mainstream."
Professor Milne has recently finished an update of IDSI's Image Interpretation Manual, a guide on the diagnostic information provided by CTLM images for physicians who are new to CTLM technology.
The Company's CTLM system recently entered US clinical trials to gather data for submission of a PMA application.
Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. The CTLM system is limited by United States Federal Law to investigational use only in the United States. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.
Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com
Photo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comImaging Diagnostic Systems, Inc.CONTACT: Investor Relations, Rick Lutz, +1-404-261-1196, orlcgroup@mindspring.com, for Imaging Diagnostic Systems
Web site: http://www.imds.com/